-
Mashup Score: 90
Original Article from The New England Journal of Medicine — Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Source: www.nejm.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Proton pump inhibitor (PPI) use may negatively impact chemotherapy outcomes in patients with endometrial cancer, a study suggests.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Endometrial cancer — sometimes referred to as uterine cancer — is the most common cancer of the female reproductive organs.
Source: blog.dana-farber.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Examining Disparities in Endometrial Cancer Outcomes Among Black Patients - The ASCO Post - 9 month(s) ago
“We’ve known for years that Black [patients] with endometrial cancer have lower survival rates than White [patients], largely because they are more likely to have an aggressive subtype and to be diagnosed at an advanced stage. But our study found this disparity persists even w hen we compare patients with the lowest-risk [type of endometrial cancer] diagnosed at the earliest possible stage,” explained lead study author Kristin Taylor, MD, Assistant Professor of Obstetrics and Gynecology at Cedars-Sinai.
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer - PubMed - 9 month(s) ago
The significance level for PFS was only met in the audited analysis. However, a preliminary analysis of a prespecified exploratory subgroup of patients with TP53wt EC showed promising results with selinexor maintenance therapy.
Source: pubmed.ncbi.nlm.nih.govCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 11Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer - 9 month(s) ago
PURPOSE The molecular classification of endometrial cancer (EC) has proven to have prognostic value and is predictive of response to adjuvant chemotherapy. Here, we investigate its predictive value for response to external beam radiotherapy (EBRT) and vaginal brachytherapy (VBT) in early-stage endometrioid EC (EEC). METHODS Data of the randomized PORTEC-1 trial (n = 714) comparing pelvic EBRT with no adjuvant therapy in early-stage intermediate-risk EC and the PORTEC-2 trial (n = 427) comparing VBT with EBRT in early-stage high-intermediate-risk EC were used. Locoregional (including vaginal and pelvic) recurrence-free survival was compared between treatment groups across the four molecular classes using Kaplan-Meier’s methodology and log-rank tests. RESULTS A total of 880 molecularly classified ECs, 484 from PORTEC-1 and 396 from PORTEC-2, were included. The majority were FIGO-2009 stage I EEC (97.2%). The median follow-up was 11.3 years. No locoregional recurrences were observed in EC
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Treatment Strategies in Non-Responders to Chemotherapy - 10 month(s) ago
Bradley J. Monk, MD, FACS, FACOG, and Christian Marth, MD, PhD, share treatment approaches to patients with endometrial cancer with a low response rate to chemotherapy, highlighting a biomarker-based approach.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab - 10 month(s) ago
The incidence of uterine cancer and its associated mortality rate are increasing. This article reports key adverse reactions in patients with advanced endometri
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Out @FDA 🇺🇸expands Dostarlimab for endometrial cancer RUBY💎trial out earlier in @NEJM saw Dostarlimab, combined w/carboplatin-paclitaxel had improvement in #EndometrialCancer especially in mismatch repair-deficient, MSI-high tumors🧬 @OncoAlert 🚨 https://t.co/cvHWuMns05 https://t.co/5onuabh3jv